Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Investigate the Effect of SB-705498 on Chronic Cough

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: October 13, 2011
Last updated: January 26, 2012
Last verified: January 2012

October 13, 2011
January 26, 2012
April 2011
December 2011   (final data collection date for primary outcome measure)
  • Blood levels of drug [ Time Frame: up to 10 hours post dose ] [ Designated as safety issue: Yes ]
  • capsaicin concentration required to achieve C5 [ Time Frame: post dose ] [ Designated as safety issue: No ]
  • 24 hour cough count [ Time Frame: various ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01476098 on Archive Site
  • capsaicin concentration required to reach C2 [ Time Frame: post dose ] [ Designated as safety issue: No ]
  • safety parameters [ Time Frame: various ] [ Designated as safety issue: Yes ]
  • changes in CQLQ [ Time Frame: various ] [ Designated as safety issue: No ]
  • VAS scale [ Time Frame: various ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
A Study to Investigate the Effect of SB-705498 on Chronic Cough
Two Part Study to Investigate Pharmacokinetics (PK) & Pharamcodynamics (PD) of SB-705498 in Cough. Part A:Open Label Study in Healthy Subjects to Determine Exposure to SB-705498. Part B:Double-blind, Placebo Controlled, Cross Over Study to Investigate Effect of SB-705498 on Capsaicin Induced Cough and 24 Hour Cough Counts in Cough Patients
This study is designed to loook at the affect of oral SB-705498 on cough following an inhaled capsaicin challenge
Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Chronic Cough
  • Drug: Placebo
    SB-705498 placebo
  • Drug: SB-705498
    400 or 600mg oral SB-705498
  • Placebo Comparator: Arm 1
    incremental doses capsaicin
    • Drug: Placebo
    • Drug: SB-705498
  • Active Comparator: Arm 2
    incremenrtal doses casaicin
    • Drug: Placebo
    • Drug: SB-705498
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female between 30 -75 (Part A) and 18-75 (Part B) years of age inclusive.
  • Non-child bearing women or women of child bearing potential if they agree to use contraception as indicated by the protocol
  • Non-smoker for at least 6 months with a pack history <5 pack years (Pack years = (No. of cigarettes smoked/day/20) x No. of years smoked).
  • Body weight > 50 kg and body mass index (BMI) within the range 19 - 30.0 kg/m2 (inclusive).
  • Capable of giving written informed consent.
  • Agree to use contraception listed as acceptable
  • Normal 12-lead ECG at screening.
  • Chronic cough (Part B only)
  • Good general health, apart from chronic cough (part B only), as determined by a responsible physician.

Exclusion Criteria:

  • A history of gastrointestinal, hepatic, renal or multiple cardiovascular risk factors.
  • Positive pre-study drug/alcohol screen.
  • Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  • A positive test for human immunodeficiency virus (HIV) antibody (if determined by the local standard operating procedures (SOPs)).
  • History of regular alcohol consumption within 6 months of the study.
  • Exposure to more than four new chemical entities within 12 months prior to the start of the study.
  • Participation in a clinical trial with a new molecule entity or any other clinical trial within 30 days of the start of the study.
  • Use of prescription or non-prescription drugs, as well as of vitamins, herbal and dietary supplements (including St John's Wort) within 7 days prior to study.
  • known history of lung cancer
  • current treatment with oral corticosteriods or other immunosupressive agents
  • FEV1 less than 80% of predicted value at screening
  • Any subject who does not reach C5 following 250uM oral capsaicin
  • History of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation.
  • Donation of blood or blood products in excess of 500mL within a 56 day period prior the start study.
  • Pregnant females as determined by positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.
  • Lactating females.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to dosing.
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP